Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1995 1
1998 1
2004 1
2007 5
2008 10
2009 22
2010 35
2011 24
2012 16
2013 11
2014 6
2015 8
2016 4
2017 8
2018 4
2019 2
2020 2
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 22424640

148 results
Results by year
Filters applied: . Clear all
Page 1
Major achievements in hepatocellular carcinoma.
Bruix J, Llovet JM. Bruix J, et al. Lancet. 2009 Feb 21;373(9664):614-6. doi: 10.1016/S0140-6736(09)60381-0. Lancet. 2009. PMID: 19231618 No abstract available.
Sorafenib, doesn't it have any competitor in advanced hepatocellular carcinoma?
Kim DY, Han KH. Kim DY, et al. J Gastroenterol Hepatol. 2011 Nov;26(11):1585-6. doi: 10.1111/j.1440-1746.2011.06901.x. J Gastroenterol Hepatol. 2011. PMID: 22011294 No abstract available.
Recurrent hepatocellular carcinoma in liver transplant recipients: parameters affecting time to recurrence, treatment options and survival in the sorafenib era.
Pfiffer TE, Seehofer D, Nicolaou A, Neuhaus R, Riess H, Trappe RU. Pfiffer TE, et al. Tumori. 2011 Jul-Aug;97(4):436-41. doi: 10.1700/950.10394. Tumori. 2011. PMID: 21989430
Hepatocellular carcinoma: sorafenib before liver transplantation?
Braillon A. Braillon A. Hepatology. 2010 Jun;51(6):2232-3. doi: 10.1002/hep.23439. Hepatology. 2010. PMID: 20041410 No abstract available.
Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation.
TAN WF, Qiu ZQ, YU Y, RAN RZ, YI B, LAU WY, LIU C, QIU YH, FENG FL, WANG JH, YAN PN, ZHANG BH, WU MC, LUO XJ, JIANG XQ. TAN WF, et al. Acta Pharmacol Sin. 2010 Dec;31(12):1643-8. doi: 10.1038/aps.2010.124. Epub 2010 Nov 22. Acta Pharmacol Sin. 2010. PMID: 21102481 Free PMC article.
Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma.
Sinakos E, Dedes I, Papalavrentios L, Drevelegas A, Akriviadis E. Sinakos E, et al. Scand J Gastroenterol. 2010 Apr;45(4):511-2. doi: 10.3109/00365521003628335. Scand J Gastroenterol. 2010. PMID: 20113152 No abstract available.
Targeted therapies: Role of sorafenib in HCC patients with compromised liver function.
Di Maio M, Daniele B, Perrone F. Di Maio M, et al. Nat Rev Clin Oncol. 2009 Sep;6(9):505-6. doi: 10.1038/nrclinonc.2009.114. Nat Rev Clin Oncol. 2009. PMID: 19707242 No abstract available.
148 results
Jump to page
Feedback